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Abstract: A novel strain of coronoviridae (SARS-CoV-2) was reported in Wuhan China in December
2019. Initially, infection presented with a broad spectrum of symptoms which typically included
muscle aches, fever, dry cough, and shortness of breath. SARS-CoV-2 enters cells via ACE2 receptors
which are abundant throughout the respiratory tract. However, there is evidence that these receptors
are abundant throughout the body, and just as abundant in cholangiocytes as alveolar cells, posing the
question of possible direct liver injury. While liver enzymes and function tests do seem to be deranged
in some patients, it is questionable if the injury is due to direct viral damage, drug-induced liver
injury, hypoxia, or microthromboses. Likely, the injury is multifactoral, and management of infected
patients with pre-existing liver disease should be taken into consideration. Ultimately, a vaccine is
needed to aid in reducing cases of SARS-CoV-2 and providing immunity to the general population.
However, while considering the types of vaccines available, safety concerns, particularly of RNA- or
DNA-based vaccines, need to be addressed.
Keywords: SARS-CoV-2; COVID-19; liver; drug induced liver injury; microthromboses; viral damage
1. Introduction
A novel strain of coronaviridae (SARS-CoV-2) was first reported in the Wuhan province of China
in December 2019. As of 8 May 2020, it has spread to 215 countries with 265,961 deaths worldwide [1].
On 11 March 2020, the World Health Organisation categorised the outbreak as a pandemic [2,3].
The SARS-CoV-2 virus is a single stranded RNA, enveloped, beta coronavirus characterised by
spikes protruding from the surface [4]. Normally found in mammals, birds, and reptiles, this strain has
not previously been identified in humans [5]. Previous strains of coronavirus outbreaks in humans
include Middle East Respiratory Syndrome (MERS) in 2012 and Severe Acute Respiratory Syndrome
(SARS) in 2003 [5,6].
Similar to SARS, SARS-CoV-2 is primarily transmitted by respiratory droplets produced by
infected persons when they sneeze, cough, or are deposited on surfaces, where they are transmitted
through contact. However, as SARS-CoV-2 has been detected in the gastrointestinal tract, urine and
saliva, other routes of transmission have been considered [7,8].
COVID-19 disease refers to infection with the SARS-CoV-2 virus. Incubation time is within
14 days following exposure, with a median of four days [7,9]. Although often asymptomatic (with
frequency estimated between 17% and 88% of cases) [10–14], infection initially presents with a broad
spectrum of symptoms that typically includes general malaise, fever (commonly over 37 ◦C), dry cough,
shortness of breath, anosmia/dysgueusia, headaches, and muscle aches [7,11,15–17]. Some other viral
related symptoms, albeit less common, can also be seen—sore throat, chest pain, nausea, vomiting,
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diarrhoea, skin rashes, and vasculitic manifestations. Severe infection seems to present a biphasic
pattern [18–21]. A first phase (‘viremia’), corresponding to viral invasion of the body, causes symptoms
as described above. This phase is followed by an ‘inflammatory’ phase, corresponding to excessive
host inflammatory response (‘cytokine storm’), responsible for severe cardiopulmonary manifestations,
sometimes leading to acute respiratory distress syndrome, shock, and death [18–21]. Respiratory
symptoms, in particular hypoxia, have been the main indication for hospitalisation.
It has been reported that 14.8–53% of SARS-CoV-2 patients had liver injury indicated by abnormal
liver function tests—mainly elevated alanine aminotransferase (ALT), hypoalbuminemia, and elevated
gamma-glutamyl transferase (GGT) [22–24]. These abnormalities seem to occur during either the
viremia or inflammatory phase. Reduced albumin can be due to inflammatory response while raised
levels of GGT and bilirubin are associated with biliary damage. This is confirmed in recent reports that
SARS-CoV-2 has a much greater affinity for biliary cells (cholangiocytes), which have higher expression
of ACE2 receptors compared with hepatocytes [7,22,25]. Significant liver injury with raised levels
of ALT, Bilirubin, variable levels of alkaline phosphatase and GGT has been reported in 58–78% of
patients with severe clinical manifestations of COVID-19 disease, being a surrogate marker for adverse
outcome [4,7,15,22,25].
This review summarises the up to date knowledge on liver injury in the context COVID-19 disease
in patients with or without pre-existing liver disease. We also discuss possible mechanisms of liver
injury and the current advice regarding management of liver disease patients including liver transplant
recipients (Table 1).
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and reflect the degree of inflammatory
response, direct biliary injury by the virus, the presence or absence of ischemia/microthromboses,
and possible drug-induced liver injury. Hypoalbuminaemia and high transaminases levels are
associated with poor prognosis.
Albumin Transaminases GGT Bilirubin Alkaline Phosphatase
COVID-19
Severe liver injury from
inflammatory response
(cytokine storm)
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2. Viral Entry and Effect on Liver 
SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive transmission [26]. 
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abundant in alveolar cells accounting for the viral injury to lungs of infected patients 
[22]. While there is conflicting evidence of ACE2 receptor density in the liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes, 
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7% 
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vomiting, diarrhoea, skin rashes, and vasculitic manifestations. Severe infection seems to present a 
biphasic pattern [18–21]. A first phase (‘viremia’), corresponding to viral invasion of the body, causes 
symptoms as described above. This phase is followed by an ‘inflammatory’ phase, corresponding to 
excessive host inflammatory response (‘cytokine storm’), responsible for severe cardiopulmonary 
manifestations, sometimes leading to acute respiratory distress syndrome, shock, and death [18–21]. 
Respiratory symptoms, in particular hypoxia, have been the main indication for hospitalisation. 
It has been reported that 14.8%–53% of SARS-CoV-2 patients had liver injury indicated by 
abnormal live  function tests—mainly elevated alanine aminotransferase (ALT), hyp albuminemia, 
and elevated gamma-glutamyl transferase (GGT) [22–24]. These abnormalities seem to occur during 
either the viremia or inflammatory phase. Reduced albumin can be due to inflammatory response 
while raised levels of GGT and bilirubin are associated with biliary damage. This is confirmed in 
recent reports that SARS-CoV-2 has a much greater affinity for biliary cells (cholangiocytes), w ich 
have higher expression of ACE2 rece tors compared with hepatocytes [7,22,25]. Significant liver 
injury with raised levels of ALT, Bilirubin, variable levels of alkaline phosphatase and GGT has been 
reported in 58%–78% of patients with severe clinical manifestations of COVID-19 disease, being a 
surrogate marker for adverse outcome [4,7,15,22,25]. 
This review summarises the up to date knowledge on liver injury in the context COVID-19 
disease in patients with or without pre-existing liver disease. We also discuss possible mechanisms 
of liver injury and the current advice regarding management of liver disease patients including liver 
transplant recipients (Table 1). 
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and reflect the degree of 
inflammatory response, direct biliary injury by the virus, the presence or absence of 
ischemia/microthromboses, and possible drug-induced liver injury. Hypoalbuminaemia and high 
transaminases levels are associated with poor prognosis. 
    
Albumi
n 
Transaminas
es GGT 
Bilirubi
n 
Alkaline 
Phosphatase 
COVID-
19 
Severe liver injury from 
inflammatory response 
(cytokine storm)  
 
 
Variabl
e  
 Variable 
Drug nduced liver 
injury 
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Direct biliary injury Variabl
e  
Variable 
 
 
 
Ischemia/microthrombo
sis 
 
 
Variabl
e  
 
Variable 
2. Viral Entry and Effect on Liver 
SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive transmission [26]. 
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abundant in alveolar cells accounting for the viral injury to lungs of infected patients 
[22]. While there is conflicting evidence of ACE2 receptor density in the liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes, 
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7% 
Variable Variable
Drug induced
liver injury Variable
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vom ting, diarrhoea, skin rashes, and vasculitic manifestations. Severe infecti n seems to present a 
biphasic pattern [18–21]. A first phase (‘viremia’), corresponding to viral invasion of the body, causes 
symptoms as described above. This phase is followed by an ‘inflammatory’ phase, corresponding to 
excessive host inflammatory response (‘cytokine storm’), responsible for severe cardiopulmonary 
manifestations, sometimes leading to acute respiratory distress syndrome, shock, and death [18–21]. 
Respiratory symptoms, in particular hypoxia, have been the main indication for hospitalisation. 
It has been reported that 14.8%–53% of SARS-CoV-2 patients had liver injury indicated by 
abnormal liver function tests—mainly elevated alanine aminotransferase (ALT), hypoalbuminemia, 
and elevated gamma-glutamyl transferase (GGT) [22–24]. These abnormalities seem to occur during 
either the viremia or inflammatory phase. Reduced albumin can be due to inf ammatory esponse 
while raised levels of GGT and bilirubin are associated with biliary damage. This is confirmed in 
recent reports that SARS-CoV-2 has a much greater affinity for biliary cells (cholangiocytes), which 
have higher expression of ACE2 receptors compared with hepatocytes [7,22,25]. Significant liver 
injury with raised levels of ALT, Bilirubin, variable levels of alkaline phosphatase and GGT has been 
reported in 58%–78% of pati nts with sev re clinical manifestations of COVID-19 disease, being a 
surrogate marker for adverse outcome [4,7,15,22,25]. 
This review summarises the up to date knowledge on liver injury in the context COVID-19 
disease in patients with or without pre-existing liver disease. We also discuss possible mechanisms 
of liver injury and the current advice regarding management of liver disease patients including liver 
transplant recipients (Table 1). 
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and reflect the degree of 
inflammatory response, direct biliary injury by the virus, the presence or absence of 
ischemia/microthromboses, and possible drug-induced liver injury. Hypoalbuminaemia and h gh 
transaminas s levels are associated with poor prognosis. 
    
Albumi
n 
Transaminas
es GGT 
Bilirubi
n 
Alkaline 
Phosphatase 
COVID-
19 
Severe liver injury from 
infl mmatory response 
(cytokine storm)  
 
 
i l
  
 i l  
Drug induced liver 
injur  
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Di ect bilia y injury Variabl
e  
Variable 
 
 
 
Ischemia/microthrombo
sis 
 
 
Variabl
e  
 
Variable 
2. Viral Entry and Effect on Liver 
SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive transmission [26]. 
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abundant in alveolar cells accounting for the viral injury to lungs of infected patients 
[22]. While there is conflicting evidence of ACE2 receptor density in the liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes, 
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7% 
Variable Variable Variable
Direct biliary injury Variable Variable
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vomiting, diarrhoea, skin rashes, and vasculitic manifestations. Severe infecti  seems to present a 
biphasic pattern [18–21]. A first phase (‘viremia’), corresponding to viral invasion of the body, causes 
symptoms as described above. This phase is follow  by an ‘inflammatory’ phase, corresponding to 
excessive host inflammatory response (‘cytokin  storm’), respo sible for severe cardiopulmonary 
manifestations, sometimes lea ing to acute respiratory distress syndr me, shock, and death [18–21]. 
Respiratory s mptoms, in particular hypoxia, have been the main indication for hospitalisation. 
It has been reported that 14.8%–53% of SARS-CoV-2 patients had liver i jury indicated by 
abn rmal liver function tests—mainly elevated alanine a inotransferase (ALT), hypoalbuminemia, 
and elevated gamma-glutamyl transferase (GGT) [22–24]. These abnormalities seem to occur during 
either the viremia or inflammatory phase. Reduced albu in can be due to inflammatory response 
while raised levels of GGT and bilirubin are associated with biliary damage. This is confirmed in 
recent r ports that SARS-CoV-2 has a uch greater affinity for biliary cells (cholangiocytes), which 
have higher expression of ACE2 receptors compared with hepatocytes [7,22,25]. Significant liver 
inj ry with raised levels of ALT, Bilirubin, variable levels of alkaline phosphatase and GGT has been 
reported in 58%–78% of patients with severe clinical manifestations of COVID-19 disease, being a 
surrogate marker for adverse outcome [4,7,15,22,25]. 
This review summarises the up to date knowledge on liver injury in the context COVID-19 
disease in patients with or without pre-existing liver disease. We also discuss possible echanisms 
of liver injury and the current advice regarding management of liver disease patients including liver 
transplant recipients (Table 1). 
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and reflect the degree of 
inflammatory response, direct biliary injury by the virus, the presence or absence of 
ischemia/microthro boses, and possible drug-induced liver injury. Hypoalbuminaemia and high 
transaminases levels are associated with poor prognosis. 
    
Albumi
n 
Transaminas
es GGT 
Bilirubi
n 
Alkaline 
Phosphatase 
COVID-
19 
Severe liver injury from 
inflammatory response 
(cytokine storm)  
 
 
Variabl
e  
 V riable 
Drug induced liver 
injury 
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Direct biliary injury Variabl
e  
Variable 
 
 
 
Ischemia/microthrombo
is 
 
 
V riabl
e  
 
Variable 
2. Viral Entry and Effect on Liver 
SARS-CoV-2 enters t e host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-C V-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive transmission [26]. 
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abun ant in alveolar cells acc unting for the vir l injury to lungs of infected patients 
[22]. While there is conflicting evidence of ACE2 receptor density in the liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes, 
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7% 
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vomiting, diarr oea, skin rashes, and vascul tic manifestations. Sev re infection seems to present a 
biphasic pattern [18–21]. A first phase (‘vir mia’), correspo ding to viral invasion of the body, causes 
symptoms as described above. This phase is followed by an ‘infl mmatory’ phase, corresponding to 
excessive h st inflammator  respo se (‘cytokine storm’), e ponsi le for severe cardiopulmonary 
manif stations, some imes l ading to acute respiratory distress syndrome, s ock, and death [18–21]. 
Respiratory symptoms, in particular hypoxia, have been the main i dication for hospitalisation. 
It as been reported that 14.8%–53% f SARS-CoV-2 patients had liver injury indicated by 
abnormal liver function tests—mainly elevated al ine minotransferase (ALT), hyp albuminemia, 
and elevated gamma-glutamyl transferase (GGT) [22–24]. These abnormalities seem to occur during 
either the vire ia or inflammatory ph se. Reduced albumin can be due to inflammatory response 
while raised levels of GGT nd bilirubin are associated with biliary damage. This is confirmed in 
recen  reports that SARS-CoV-2 h s a much greater affinity for bili ry cells (cholangiocytes), which 
hav  higher expression of ACE2 receptors com ared with hepatocytes [7,22,25]. Significant liver 
injury with r ised levels of ALT, Bi irubin, variable levels of alkaline phosphatase and GGT has been 
reported in 58%–78% of patients w th severe clinical manifestations of COVID-19 disease, being a 
su r gate marker for adverse outcome [4,7,15,22,25]. 
This review summarises the up to date knowledge on liver injury in the context COVID-19 
disease in patients with or without pre-existing liver disea e. We al o discuss possible mechanisms 
of liver inju y an  the current advice re ardi g managem nt of liv r disease patients including liver 
transplant r cipients (Table 1). 
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and flect the degree of 
inflammatory response, direct biliary inju y by the virus, the pr sence or absence of 
ischemia/microthromboses, and possible drug-induced liver injury. Hypoalbuminaemia and high 
trans mina es levels are ass ciated with poor prognosis. 
    
Albumi
n 
Transaminas
es GGT 
Bi irubi
n 
Alkaline 
Phosphatase 
COVID-
19 
Severe liver injury from 
inflammatory response 
(cytokine storm)  
 
 
Variabl
e  
 Variable 
Drug induced liv r 
injury 
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Direct biliary injury Variabl
e  
Variable 
 
 
 
Ischemia/micr thrombo
sis 
 
 
Variabl
e  
 
Variable 
2. Viral Entry and Effect on Liver 
SARS-CoV-2 enters the host via the Angiotensi -converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive tra smission [26]. 
ACE2 is found in a variety of tissues (heart, liv lung, bladder, kidney, and pancreas); however, 
it is know  o be abu ant in alveolar cells accounting for the viral injury to lungs of infected patients 
[22]. While there is co flicting evidence of ACE2 recep or density in the liver, c rrent reports using 
single-c ll RNA seque c ng have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. use  i  silic and in vitro techniques to sample hepatocytes, 
cholangio ytes, Kupffer cells and other component  of fresh liver samples [25]. They found that 59.7% 
Path gens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vom ting, diarrhoea, kin rashes, an vasculitic manifestation . Severe infection seems to present a 
biphasic pa tern [18–21]. A first pha e (‘viremia’), corresponding o viral inv sion of the body, causes 
symptom as escribed b ve. This phase i  follow d by a  ‘ flammat ry’ phase, corresponding to 
excessive ho t inflammatory response (‘cyt kine storm’), responsible for severe cardiopulmonary 
ma ifes ations, s metimes leadi g t  ac te respiratory distress syn rome, shock, and death [18–21]. 
Re p rato y sympt ms, n particular hypoxia, have been the main ndicatio for hospitalisation. 
It has bee  reported th t 14.8%–53% of SARS-CoV-2 patients had liver injury indicated by 
bnormal liver fu ction tests—mainly levated alani e a otransferase (ALT), hypoalbuminemia, 
and elevated gamm -glutamyl transfer se (GGT) [22–24]. Th se abn rmalities seem to occur during 
either the viremia or inflammatory phase. Reduced albumin can be due to i flammatory response 
while raise  levels of GGT and bilirubin are associ ted with bil ary damage. This is confirmed in 
rec nt r p rts that SARS-CoV-2 s a much gre ter affinity for biliary cells (cholangiocytes), which 
have higher ex ressi n of ACE2 rec ptors compared with hepatocytes [7,22,25]. Significant liver 
injury with ais d levels of ALT, Bilirubin, v r able levels of alkali e phosphatase and GGT has been 
rep rted n 58%–78% of patients with severe clinical manif stations of COVID-19 disease, being a 
surrogat  marker for adverse outcome [4,7,15,22,25]. 
This r vi w summarises the up t  da e kn wledge on liver injury in the context COVID-19 
diseas in patients with or without pre-exi ting liver disease. We also discus  possible mechanisms 
of live  i jury and th  current dvic  r garding manageme  of liver disease patients including liver 
transp ant recipients (Table 1). 
Table 1. Liver nzyme abno malit es in COVID-19 disease vary and reflect the degree of 
inflammatory response, direct biliary injury by th  virus, th  presence or absence of 
isch mia/microthromboses, and possib e drug-induced liver injury. Hypoalbuminaemia and high 
t ansaminases levels are associated with poor prognosis. 
    
Albumi
n 
Transaminas
es GGT 
Bilirubi
n 
Alkaline 
Phosphatase 
COVID-
19 
Severe liver injury from 
inflamm tory response 
(cytokine storm)  
 
 
Variabl
e  
 Variable 
Drug induced live  
injury 
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Direct iliary injury Variabl
e  
Variable 
 
 
 
Ischemia/microthrombo
sis 
 
 
Variabl
e  
 
Variable 
2. Viral Entry and Effect on Liver 
SARS-C V-2 e ters the ho t via th  A iotensin-conver ing nzyme 2 (ACE2) receptor. It has 
been suggested that S RS-CoV-2 binds ACE2 receptors more fficiently than previous COVID 
virus s, all wing for it  extensive transmission [26]. 
ACE2 is ound in a v iety of tissues (heart, live , lung, bladde , kidney, and pancreas); however, 
it is k own t  b  abund nt in alveola  cells accounti g for the viral injury to lung  of infected patients 
[22]. While there is conflicti g ev dence of ACE2 receptor den ty in the liver, current reports using 
single-cell RNA seque cing have co firmed that cholangiocytes have the highest levels of ACE2 
rec ptors [7,22,25,27]. Hu et l. used n sili o and in vitro techniques to ample hepatocytes, 
cholangiocytes, Kupffer cells and oth r compon nts of fresh liver samples [2 ]. They found that 59.7% 
Ischemia/
microthrombosis
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 10 
 
vomiting, diarrhoea, skin rashes, and vasculitic manifestations. Severe infection seems to present a 
biphasic pattern [18–21]. A first phase (‘ iremia’), corresponding to viral i vasion f th  body, cau s 
symptoms as described above. This phase is followed by an ‘i flammatory’ ph e, correspon ing to 
excessive ho t inflammatory response (‘cytokine storm’), respo sible for severe cardiopulmonary 
manifestations, ometi es leading t  cute respiratory istress syndr m , shock, and death [18–21]. 
Respiratory symptoms, in particular ypoxi , have been the in indication for hos it lisation. 
It has been re orted that 14.8%–53% f SARS-CoV-2 patients had liver i jury indicated by 
abnormal liver function tests— ai ly elev ted alanine aminotransf ra e (ALT), hypoalbuminemia, 
and elevated gamma-glutamyl transferase (GGT) [22–24]. These abnor alities seem to occur during 
either the ir mia or inflammatory phase. Reduced albumin c n be due to i fl mmatory response 
while raised lev ls of GGT nd b lirubin r  associated with bili ry damage. T is is confirmed in 
recent r ports that SARS-CoV-2 has a m ch greater ffi ity for bili ry cells (chol ngiocytes), which 
have higher expression of ACE2 receptors ompared with hepatocytes [7,22,25]. Sig ific nt liver 
injury with raised level  f ALT, Bilirubin, va iable levels of alkaline ph sphatase an  GGT has been 
reported in 58%–78% of p tients ith severe cli ical manifest tions of COVID-19 disease, being  
sur ogate marker for adverse outcome [4,7,15,22,25]. 
This review summarises the up to date knowledge n liver injury i  t e context COVID-19 
disease in patients with or w thout pre-existing liver diseas . We also discuss possible mechanisms 
of liver injury and the current advice regarding manag ment of liver di ease patients i c uding liver 
tran plant recipients (Table 1). 
Table 1. Liver enzyme abnormalities in COVID-19 disease vary and reflect the degree of 
inflammatory response, direct bili ry injury by the virus, the presence or absenc  of
ischemia/ icr thrombose , an  possi le drug-induced liver inju y. Hypoalbumi aemia and high 
tran aminases levels are associated with poor p o nosis. 
    
Albumi
n 
Transa inas
es GGT 
Bilirubi
n 
Alkaline 
Phosphat se 
COVID-
19 
Severe liver injury fro  
inflammatory re ponse 
(cytokine storm)  
 
 
Variabl
e  Variable
Drug induced liver 
i jury 
Variabl
e 
 
Variabl
e 
Variabl
e 
Variable 
Direct biliary injury Variabl
e  
Variable 
 
 
 
Ischemia/microthrombo
sis 
 
 
Variabl
e  
 
Variable 
2. Viral Entry and E ct on Liver 
SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COV D 
virus s, allowing for its extensive transmission [26]. 
ACE2 is f und in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abundant in alveolar cells accounting for the vir l injury to lu s of infect d patients 
[22]. While there is conflicti g evi ce of ACE2 receptor ensity in t e liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. sed in silic  and in vitro techniques to s mple hepatocytes, 
cholangiocytes, Kupffer cells and other c mponents of fresh li er samples [25]. They found t at 59.7% 
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SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has 
been suggested that SARS-CoV-2 binds ACE2 receptors more efficiently than previous COVID 
viruses, allowing for its extensive transmission [26]. 
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however, 
it is known to be abundant in alveolar cells accounting for the viral injury to lungs of infected patients 
[22]. While there is conflicting evidence of ACE2 receptor density in the liver, current reports using 
single-cell RNA sequencing have confirmed that cholangiocytes have the highest levels of ACE2 
receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes, 
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7% 
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2. Viral Entry and Eff c on Liver
SARS-CoV-2 enters the host via the Angiotensin-converting enzyme 2 (ACE2) receptor. It has
been sugg sted that SARS-C V-2 inds ACE2 recep s ore efficiently tha pr vious COVID viruses,
allowing for its extensive transmission [26].
ACE2 is found in a variety of tissues (heart, liver, lung, bladder, kidney, and pancreas); however,
it is known to be b ndant in alveolar cells account ng for the viral injury to lungs of infected
patients [22]. While th re is conflicting ev de ce of CE2 r c ptor density in the liv r, current repo ts
using single-cell RNA sequencing hav confi med that cholangiocyt s have th highest levels of
ACE2 receptors [7,22,25,27]. Hu et al. used in silico and in vitro techniques to sample hepatocytes,
cholangiocytes, Kupffer cells and other components of fresh liver samples [25]. They found that 59.7%
of cholangiocytes ad ACE2 receptors in comparison to only 2.6% f hepa ocyt s. This data sugg sts
that cholangiocytes have the same percentage of ACE2 receptors as aveolar type 2 cells [25]. Further,
it has been suggested that infection of cholangiocytes may be the source of the virus found in faeces [28].
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While the presence of a receptor is needed for the virus to gain entry into the host, it is still unclear if
other conditions are also needed or could possibly aid the virus.
3. Possible Causes of Elevated Liver Enzymes
Emerging data for abnormal liver enzymes seen in SARS-CoV-2-infected patients raises several
questions. Are these abnormalities due to direct viral damage, drug-induced liver injury (DILI),
unknown pre-existing liver disease, or indirect consequence of viral damage to other systems
(cardiopulmonary, haemostasis)? Liver samples from infected patients were examined, and moderate
microvascular steatosis with mild lobular and portal activity were reported [29]. It does seem likely
that damage that may affect liver function could principally be due to hypoxia and shock, although a
direct effect of SARS-CoV-2 to the liver or DILI can also be contributing factors [29,30].
3.1. Direct Viral Damage
While mechanisms of direct damage to the liver remain unclear, concerns about viral damage have
already been raised, e.g., with a case of SARS-CoV-2 infection concurrent with liver failure, without
other apparent cause, recently described in Germany [31].
However, direct viral damage has been contested by some, and other explanations have been
offered, which will be discussed below [30] (Figure 1).
Pathogens 2020, 9, x FOR PEER REVIEW 3 of 10 
 
of cholangiocytes had ACE2 receptors in comparison to only 2.6% of hepatocytes. This data suggests 
that cholangiocytes have the same percentage of ACE2 receptors as aveolar type 2 cells [25]. Further, 
it has been suggested that infection of cholangiocytes may be the source of the virus found in faeces 
[28]. While the presence of a receptor is needed for the virus to gain entry into the host, it is still 
unclear if other conditions are also needed or could possibly aid the virus. 
3. ossi le a ses of levate  iver zy es 
E erging data for abnor al liver enzy es see  in S S- o -2-infected patients raises several 
questions. re t ese a r alities e t  irect iral a a e, r -i ce  li er i j r  ( I I), 
unk o  re-existi g liver disease, or i irect conseq e ce of viral da age to other syste s 
(cardiopulmonary, haemostasis)? Liver samples from infected patients ere exa ined, and o erate 
icrovasc lar steatosis it  il  lob lar an  portal activity ere reported [29]. It oes see  likely 
that da age that may affect liver function could principally be due to hypoxia and shock, although 
a direct effect of SARS-CoV-2 to the liver or DILI can also be contributing factors [29,30]. 
3.1. irect iral a age 
hile mechanisms of direct damage o the liv r remai  unclear, co cerns about viral dam ge 
have already be n raised, e.g., with a case of SARS-CoV-2 infection concurrent with liver failure, 
without other apparent cause, r cently described in Germany [31]. 
o e r, direct viral da age has been contested by so e, and other explanations have been 
offered, which wi l be discu sed below [30] (Figure 1). 
 
Figure 1. Liver injury in SARS-CoV-2. There are multiple reports of increased liver enzymes and liver 
dysfunction in SARS-CoV-2 patients presenting with elevated alanine transaminase (ALT), gamma-
glutamyl transferase (GGT), bilirubin, and monocyte chemoattractant protein 1 (MCP1). Taken 
together with lower levels of albumin, this points to liver damage with possible injury to biliary cells. 
Liver injury is most likely multifactorial and seen mainly in patients at the severe end of the disease 
spectrum. 
  
Figure 1. Liver injury in SARS-CoV-2. There are multiple reports of increased liver enzymes and
liver dysfunction in SARS-CoV-2 patients presenting with elevated alanine transaminase (ALT),
gamma-glutamyl transferase (GGT), bilirubin, and monocyte chemoattractant protein 1 (MCP1).
Taken together with lower levels of albumin, this points to liver damage with possible injury to biliary
cells. Liver injury is most likely multifactorial a d seen mainly i patients at the severe end of the
dis ase spectrum.
3.2. Drug-Induced Liver Injury
A study by Fan et al. [29] has raised the question of DILI as a possible cause of liver injury seen in
COVID-19 patients. They show that patients given lopinavir or ritonavir after admission presented
higher incidence of liver injury and required longer stay in hospital. It is also possible that these
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patients were given antivirals because they had a more severe presentation that might have affected
their liver in the first place. Though recent evidence suggests lopinavir and ritonavir had no clinical
effect on SARS-CoV-2, perhaps future application of antiviral drugs should also take into account their
effects on the liver [32].
Many infected with SARS-CoV-2 regularly use paracetamol as it is the recommended antipyretic
medication. Unintentional overdose with paracetamol contributing to raised ALT cannot be excluded
in patients’ non-remitting pyrexia, as paracetamol is a well-recognised cause of fulminant hepatic
failure [33]. This also needs to be taken into consideration when evaluating liver injury in these patients.
Several drugs have been trialled on SARS-CoV-2 patients such as hydroxychloroquine and
azithromycin with ambiguous results on the virus but possibly exacerbating liver injury [34].
This ambiguity leads to many questions involving the management of SARS-CoV-2 and pre-existing
liver disease.
3.3. Hypoxic Liver
Sepsis complicating severe COVID-19 illness and hypoxia can also be significant contributing
factors [30]. Hypoxic liver injury can be characterised by an increase in transaminases due to an
imbalance of oxygen supply [35]. This typically occurs in the elderly with right side congestive heart
failure [35]. Though the median age of patients contracting SARS-CoV-2 is 47 years of age, the elderly
have proven to be particularly vulnerable, with increasing age an indicator of mortality [7,27]. In the
elderly population, it is likely that a rise in liver enzymes, particularly transaminases, is due to
pre-existing conditions.
3.4. Microthromboses
SARS-CoV-2 has been shown to lead to a hypercoagulable state, therefore increasing
thromboembolism risk [36–38]. It has recently been reported that in certain patient groups, often younger
patients, micro vascular thromboses can cause end stage organ damage and may potentially affect the
liver. It is also notable that high levels of alkaline phosphatase have been used as a prognostic value
for ischemic stroke patients and in identifying high risk haemorrhagic transformation and are also
shown to be high in COVID-19 patients suffered thrombotic events, although in other cases, alkaline
phosphatase levels have been normal or very mildly raised [39–41].
Results of autopsies from Wuhan province, China, have also shown infiltration of lymphocytes
and monocytes in the portal area with microthrombosis and congestion of hepatic sinuses [27]. The liver
was described as having hepatocyte degeneration accompanied by lobular focal necrosis and neutrophil
infiltration. Though histological features of liver failure and bile duct injuries were not observed in
these cases [27].
3.5. SARS-CoV-2 in Patients with Pre-Existing Liver Disease
Patients with pre-existing conditions have shown increased susceptibility to SARS-CoV-2.
At present, it is unclear to what extent pre-existing liver disease contributes to liver injury seen
in SARS-CoV-2 patients. A very recent study conducted in the UK on more than 17 million people has
identified pre-existing liver disease as an independent risk factor of death in SARS-CoV-2 infections [42].
For instance, it has been shown that patients with SARS-CoV-2 show an increase of monocyte
chemoattractant protein 1 (MCAP1), which is a chemokine known to exacerbate steatohepatitis [34].
A recent short communication describes possible implications for patients with non-alcoholic fatty
liver disease (NAFLD) [43]. NAFLD patients, alongside those with metabolic syndrome and type
2 diabetes, are often treated with ACE inhibitors, which have anti-inflammatory and anti-obesity
effects. While there has not been a reported effect on mortality of ACE inhibitor drug use, it has
been speculated that ACE inhibitors up-regulate the ACE2 receptor and therefore can increase viral
load in patients taking these medications [43,44]. NAFLD patients often exhibit increased cytokine
levels due to their chronic inflammatory stage. Prins and Olinga suggest that this predisposition,
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in patients infected with SARS-CoV-2, could expedite the progression of NAFLD to a more aggressive
non-alcoholic steatohepatitis [43].
There is suggestion that derangement of liver function should be taken into consideration alongside
other physiological values [11,30]. Patients with SARS-CoV-2 have exhibited increased levels of creatine
kinase, lactate dehydrogenase, ferritin, C-reactive protein, and myoglobin alongside liver dysfunction,
and it has been suggested that liver damage is collateral, caused by induced cytotoxic T cells and the
induction of the innate immune response rather than direct injury from the virus itself, as observed
with other respiratory viruses [11,16,30,45].
Regardless of the source of injury, it is clear that managing those with pre-existing liver disease
needs to be thought out carefully during this pandemic and in future outbreaks of coronavirus infection.
These patients are at higher risk of being infected and of more severe COVID-19 disease and should be
practising strict social distancing or shielding if they take steroids or immunosuppressive therapies [46].
The British Liver Trust has recently called on the UK government to classify those with extreme
liver disease as ‘extremely vulnerable’ [47]. Recent reports suggest that more than 1/3 of cirrhotic
patients who developed SARS-CoV-2 died [48]. A new international registry developed between the
University of Oxford and the University of North Carolina has shown that those with decompensated
cirrhosis are at most risk and are calling on hospitals to routinely test patients with deranged liver
function/enzyme results for SARS-CoV-2 so early observation and treatment may prevent further
deterioration. The British Liver Trust also suggests that all patients with decompensated cirrhosis
practice social shielding, a step up from social distancing, even though it is not yet part of the formal
guidance [47].
Boettler et al. have published comprehensive recommendations for management and surveillance
of patients with liver disease throughout the SARS-CoV-2 outbreak [28]. This paper now forms the
official position of the European Association for the Study of Liver and the European Society of
Clinical Microbiology and Infectious Disease [49]. They suggest prioritization of outpatient clinics,
inpatient admission depending on presence of certain risk factors, reducing exposure through social
distancing (remodelling waiting areas, reduction of waiting times, reduction of face to face contact
through telemedicine), and carefully considering the benefits of patient care weighed against the risk
of infection.
4. Disease Severity in the Immunocompromised and Transplant Patients
Under ordinary conditions, organ transplant recipients and those on immunosuppressants are at
high risk of infection due in particular to the suppression of T cell response, making their susceptibility
to SARS-CoV-2 and prognosis, if infected, unclear. On one hand, it has been postulated that reduction
of systemic inflammation by immunosuppressants could improve outcome for COVID-19 patients as
the severity of inflammatory response can be an indicator of prognosis [50]. However, it is also a case
that immunosuppressed individuals tend to have a higher viral load, take longer to shed the virus,
and may show more severe clinical symptoms with a poorer prognosis [51].
Zhu et al. reported on 10 SARS-CoV-2-positive renal transplant recipients in Wuhan, China [51].
All were admitted to hospital with significant progressive pneumonia. The severity of pneumonia
in this group was recorded as greater than their infected family members and others in the local
population. In accordance with Influenza A/HINI guidance, calcineurin inhibitors were stopped in
seven patients for nine days and in one patient for 12 days [51,52]. Within this group, there was no
acute renal graft rejection, and all patients eventually recovered from COVID-19, though it took longer
for them to become SARS-CoV-2-negative than their infected family members [51]. They attributed
the length of infection but eventual recovery to the hypothesis that long-term immunosuppression
might delay viral clearance and prolong the course of disease but avoid fatal pneumonia caused by a
hyperimmune response [51].
Another study of 90 SARS-CoV-2-positive transplant patients in New York City also described
reducing antimetabolites, steroids, and/or calcineurin inhibitors in 55 patients [53]. Pereira et al.
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categorized patients as mild (outpatient care only), moderate (admission as general inpatient),
or severe (mechanical ventilation, admission to intensive care unit, or death) [53]. Within this group,
24% presented with mild disease, 46% moderate, and 30% severe. As with other studies, advanced age
and comorbidities were associated with disease severity [7,27,39–41]. Type of transplant and time of
viral infection after transplant were not statistically significant factors [53]. Laboratory values were
similar between moderate and severe cases, though albumin was lower in the severe group [53].
At present there is little data regarding the use of immunomodulatory agents such as tocilizumab
or sarilumab when trying to suppress the ‘cytokine storm’ in these patients [53]. Pereira et al. noted
that 14 patients receiving 1–3 doses each of tocilizumab and 16 patients receiving bolus steroids showed
no adverse outcomes at the time of their publication [53]. They also noted that while all biomarkers
of inflammation were elevated, procalcitonin was the only marker which differed between moderate
and severe disease and suggested that the chronically immunosuppressed may undergo a uniquely
dysfunctional inflammatory response to SARS-CoV-2. This was further supported by Lippi et al.,
who showed that high levels of procalcitonin can be a predictor of severe COVID-19 syndrome and
potentially related to secondary bacterial infection [54]. From this study there were no confirmed cases
of thromboembolic complications or organ rejection [53].
Many epidemiological reports regarding treatment and prognosis of COVID-19 syndrome are
based on the general population who would have had healthy immunity before viral infection,
thus overlooking important data for immunocompromised patients [53]. Many such patients
present with atypical signs and symptoms leading to missed diagnosis, late presentation, and worse
prognosis [50]. At the time of this publication, no significant conclusions have been drawn regarding
the outcome of COVID-19 in patients in receipt of immunosuppressive therapy. More research into
cytokine activation, T cell signalling and migration, and viral clearance are needed [53]. The postulated
anti-inflammatory benefits of immunosuppression should be balanced against the possibility of
inhibiting anti-viral immunity by delaying viral shedding and possible organ rejection for those
patients having undergone transplant [50].
5. Vaccination for SARS-CoV-2
Ultimately, a vaccine against SARS-CoV-2 will be key in preventing spread of virus and loosening
social restrictions, but many factors need to be considered in the development of a vaccine so as not to
increase innate immune response, increase likelihood of autoimmune diseases, or further DILI.
Vaccinations are costly and usually take years to complete stringent animal and human trials
before being made available to the public. However, in an epidemic or pandemic situation, the scientific
community faces increasing pressure to rapidly respond with an effective vaccine. In previous
epidemics such as Ebola, H1N1, SARS, and MERS, vaccine development was never completed due to
the epidemic ending and funds being reallocated [55].
In the context of this review, it is important to highlight that one possible side effect of vaccinations
could result in liver damage. Vaccines with the greatest potential, in pandemic situations, are RNA-
or DNA-based vaccines [55]. These vaccines do not need to be cultured or require fermentation,
they avoid risks of working with live pathogens, and can specifically encode key antigens without also
coding for other toxins, but they are not without risks [55,56].
There are no approved RNA vaccines to date, as toxicity cannot always be predicted from
animal studies due to species differences between human and animals [55]. Some effects seen in
previous RNA-based vaccinations have been pancreatitis, lactic acidosis, liver steatosis, nerve damage,
and death [55]. Liver toxicity was reported in preclinical studies using RNA therapy for Crigler–Nayjor
syndrome, and in an RNA-based rabies vaccination trial, an increased and deleterious inflammatory
response ended the trial [55]. This is possibly due to type 1 interferon induction by RNA, which is
known to induce autoimmune diseases [55]. DNA-based vaccines have also been implicated in
inducing an innate immune response through toll-like receptor (TLR) 9 and non-TLR activation [56].
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6. Conclusions
SARS-CoV-2 is a novel coronavirus known to cause respiratory infections with severity ranging
from mild cold- and flu-like symptoms to fatal pneumonia. While respiratory based, if severe, it can
cause dysfunction of other organs such as the kidneys and liver. It is likely that the liver injury seen
in SARS-CoV-2-positive patients is multifactorial and the result of a combination of inflammatory
response, sepsis, hypoxia, microthrombotic events, DILI, and viral damage. Pre-existent liver disease is
an independent risk factor of death in SARS-CoV-2 related infection, and severity of liver damage most
likely correlates with COVID-19 disease severity. Nevertheless, abnormalities in the liver function
tests of these patients, without pre-existing liver disease, may have prognostic significance and predict
adverse outcomes. Patients with chronic liver disease and in particular those on immunosuppressive
therapies including liver transplant recipients should be particularly careful and managed according
to internationally accepted guidelines regarding strict social distancing or shielding.
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